Drug intelligence / Profile preview

s-equol

Development stage
Phase 2
Lead developer
Otsuka Holdings
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Topical
01

Overview

S-equol is an orally bioavailable, non-steroidal estrogen and a metabolite of the soy isoflavone daidzein produced by certain intestinal bacteria in humans[1][4][5]. It shares structural similarities with estradiol and acts as a selective estrogen receptor modulator (SERM), binding preferentially to estrogen receptor beta (ERβ) with much lower affinity for ERα[4]. S-equol exhibits potential chemoprotective effects and has been investigated for alleviating menopausal symptoms such as hot flashes, mood swings, vaginal irritation, sleep disturbances, and bone loss. Clinical studies suggest additional benefits on cardiovascular health (e.g., lowering LDL cholesterol and arterial stiffness), skin aging reduction, and possible protective effects against osteoporosis[5][6][8]. Only about 25–50% of people naturally produce S-equol after consuming soy due to differences in gut microbiota. As a supplement or investigational agent, it is considered safe based on available data from clinical trials[4][7].

Brand names
Equelle
Other names
equolS-(-)-equol(S)-equol
02

Targets

ESR1 (ERα)ESR2 (ERβ)

Beyond the preview

Go deeper on s-equol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on s-equol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call